Floating Drug delivery System: A Novel Approach For Gastroretentive Drug Delivery


Saurabh Kumar*, A. Rahaman, L. K. Tyagi and Amrish Chandra

Department of Pharmacy, Institute of Biomedical Education and Research, Mangalayatan University, Aligarh (U.P.), India

*Corresponding Author E-mail: sahusaurabh3@gmail.com



Oral controlled drug delivery system have an important area in novel drug delivery system to achieving efficient drug delivery that have poor bioavailability and short gastric residence time(GRT). Several approaches are currently utilized in prolongation of gastric residence time, including floating drug delivery system, swelling system, Bio/muco-adhesive system, high density system, HBS, delaying gastric emptying excipients etc. In this review compile the recent available literature on gastroretentive drug delivery and marketed products have been discussed. In addition, the pharmaceutical basis of their design, their advantages and future potential for oral controlled drug delivery are discussed.


KEYWORDS: floating drug delivery systems, low density, controlled release, Buoyancy , Gastric retention.




Oral drug administration is the most widely used for drug delivery system. Approximately 50% of the drug  delivery system available in the market are oral drug delivery have recently been of increasing interest in pharmaceutical field to achieve improved therapeutic advantages, such as ease of dosing administration, patient compliance and flexibility in formulation.


Effective oral drug delivery may depend upon the factors such as gastric emptying process, gastrointestinal transit time of dosage form, drug release from the dosage form and site of absorption of drugs. Drugs that are easily absorbed from GIT and have short half lives are eliminated quickly from the systemic circulation.


Frequent dosing of these drugs is required to achieve suitable therapeutic activity. To avoid this limitation, the development of oral sustained release formulation is used to release the drug slowly into GIT and maintain the effective concentration of drug in the systemic circulation for log time. After oral drug delivery retained in the stomach, drug release in controlled manner and supplied continuously in the GIT.1 GRDDS is approach to prolong retention time in the stomach and there by improve the bioavailability, reduces wastage of drug and enhance the drug solubility that are less soluble in the intestine.


Drug that are poorly soluble in high pH are formulated as GRDF by this dosage form the drug is soluble in the stomach before the emptying the stomach.2 Certain types of drugs can benefit from using gastric retentive system. These include:3

Drugs acting locally in the stomach

Drugs that are primarily absorbed in the stomach

Drugs that is poorly soluble at an alkaline pH

Drugs with a narrow window of absorption

Drugs absorbed rapidly from the GI tract

Drugs that degrade in the colon



The stomach is J-shaped organ located in the left upper part of the abdomen immediately below the diaphragm. The stomach can also be divided into three anatomical regions (Fig.1) (Fundus, Body and Antrum).4

The main function of the stomach is to store the food and mixed or grind and then it release for the intestine.


Figure 1: Anatomy of stomach


Bioadhesive or Mucoadhesive:

These systems are used to drug delivery within the lumen and cavity of the body to in a site-specific manner. These approaches involve the use of bioadhesive polymers that can be adhere to the epithelial surface of GIT. The adherence of the delivery system to the gastric wall increases the residence time at a particular site thereby bioavailability increased. The proposed mechanism of bioadhesive is the formation of hydrogen and electrostatic bonding at the mucus polymer boundary.5,6


Swelling System:

These type of dosage form swell to an extent that prevent their exist in the stomach through the pylorus. This type of dosage form retained longer period of time in stomach. These systems may be named as “plug type system”, since they exhibit the tendency to remain logged at the pyloric sphincter.7,8


Incorporation of delaying gastric emptying excipients:

The presence of food in the stomach, drug absorption was more rapid then under fast condition. In the addition of excipients like Monoglycerides, Diglycerides and Fatty acids of chain lengths of C10 – C14  decreased gastric emptying rate.9


High density System:

These system have the density greater than that of the stomach content (1.004 gm/cm3) retained the dosage form in the lower part of the stomach. Sedimentation has been employed as a retention mechanism for high density system. For sufficient prolongation of GRT ~3 g/cm3 density required. The high density of formulation like pellets should be used. These pellets can be coated or mixed with heavy, nontoxic materials such as barium sulfate, titanium dioxide, etc.10


Ion-exchange resins:

An ion exchange resin loaded with bicarbonate shown gastric retentive property. Then a semi-permeable membrane were coated on the ion exchange resin to achieved no rapid loss of Co2 . When arrived in the acidic pH of stomach, chloride and bicarbonate ion exchange take place resultant co2 was released and trapped in the membrane thereby carrying beads toward the top of the stomach content and a floating layer of resin beads formed.11


Hydrodynamically balanced system (HBS):

These are single-unit dosage form  having gel-forming  hydrophilic polymers. The polymer is mixed with drugs and usually administered in HBS capsule. When system contact with water the capsule shell dissolves and mixture swells to form a gel barrier, which imparts buoyancy to dosage form in gastric juice for a long period.12


Magnetic System:

This approach based on incorporation of magnetically active compounds in the dosage form for site specific delivery. The system contains a small internal magnet and a magnet placed on abdomen over the position of the stomach.  Although magnetic system seems to work, the external magnet must be positioned with a degree of precision that might compromise patient compliance.13


Floating system:

Floating drug delivery systems (FDDS) have a bulk density less than gastric fluids and so remain buoyant in the stomach without affecting the gastric emptying rate for a prolonged period of time. While the system is floating on the gastric contents, the drug is released slowly at the desired rate from the system. After release of drug, the residual system is emptied from the stomach. This results in an increased GRT and a better control of the fluctuations in plasma drug concentration.14-16



According to the mechanism of buoyancy, there are two distinctly different technologies used to development of FDDS which are:

A. Effervescent System, and

B. Non- Effervescent System.


(A) Effervescent Systems:

These are matrix types of systems prepared with the help of swellable polymers such as methylcellulose and chitosan while sodium bicarbonate, tartaric acid, and citric acid used as effervescent compounds. When the formulation of these compound  contact with the acidic gastric contents, CO2 is liberated and gets entrapped in swollen hydrocolloids, which provides buoyancy to the dosage forms.17


Asnaashari et al developed metronidazole floating dosage forms for better eradication of Helicobacter Pylori in peptic ulcer diseases that are retain in the stomach for a long time by using multi-factorial design. HPMC, psyllium and carbopol in different concentrations were used as floating agents, and sodium bicarbonate was added as a gas-generating agent. Formulations containing HPMC as filler showed prolonged lag times for buoyancy. Adding psyllium to these formulations had reduced relative lag times. Overall, selected formulations were able to float and showed buoyancy for at least 8 h.18


Chen et al develop an optimal GRDDS for administering Losartan by swellable and floatable tablets combining hydroxyethyl cellulose (HEC), sodium carboxymethyl cellulose (NaCMC), and sodium bicarbonate were prepared at different compression pressures for evaluating swelling characteristics and floating capacity. At lower compression force and appropriate ratio of HEC to NaCMC, addition of sodium bicarbonate resulted in the tablets floating over SGF for more than 16 h and swelling to 2 cm in diameter within 3h.19


Nagarwal et al developed floating matrix tablets cinnarizine HCl (CNZ). floating matrix formulations containing four viscosity grades of hydroxypropyl methylcellulose, sodium alginate or polyethylene oxide, and sodium bicarbonate as gas-forming agent used. CNZ releasing data were analyzed by using Higuchi, Peppas,  Weibull, and Vergnaud models. On the basis of in-vitro release data, tablet was subjected to bioavailability studies in rabbits and was compared with CNZ suspension. Greater bioavailability achieved due to longer retention in the gastric environment.20


Bomma et al developed floating matrix tablets of norfloxacin to increase drug bioavailability. Hydroxypropyl methylcellulose (HPMC K4M, HPMC K100M) and xanthan gum used as polymer. Physical properties and In-vitro release of drug from tablet formulation was studies. Non-Fickian diffusion was confirmed as the drug release mechanism from these tablets, indicating that water diffusion and polymer rearrangement played an essential role in drug release. And Bomma found maximum retention of tablet in stomach about 180 min.21


Ichikawa et al developed a new multiple type of oral floating dosage system composed of effervescent layers and swellable membrane layers coated on sustained release pills. The inner layer was an effervescent layer, containing both sodium bicarbonate and tartaric acid was divided into two sublayers to avoid direct contact between the 2 agents and outer layer was a swellable membrane layer, containing polyvinyl acetate and purified shellac. When the system was immersed in H2O at 37şC, it settled down and the solution permeated into the effervescent layer through the outer swellable membrane. CO2 was generated by the neutralization reaction between the 2 effervescent agents, producing swollen pills (like balloons) with a density less than 1.0 g/mL. The system had good floating floating property approximately 10 min independent of pH and viscosity medium. The drug (para-amino benzoic acid) released in a sustained manner (figure-2).22


Figure 2.  (A) Multiple-unit oral floating drug delivery system.


Figure 3.  (B) Working principle of effervescent FDDS.

Bandari et al introduced a multiple biphasic tablet of fenoverine for gastroretentive drug delivery system. By this system drug released 0.1 mol L(-1) HCl and SGF (enzyme free) in sustained manner with buoyant properties. No significant change occur in dissolution profiles. HPMC containing floating multiple matrix tablet with a zero-order release profile was suitable GRDDS (Fig.3).23


Lingam et al developed a biphasic with multiple unit minitab by gas formation method. In this system loading dose have uncoated core units and prolong core units which is coated with three coating layers one is seal coat, second is effervescent and third outer layer is polymeric of polymethocrylates. With the Eutragit RL30D system was floated immediately on gastric contents and was released linear on controlled manner.24


Kulkarni et al developed bilayer floating tablets of diltiazem HCI and lovastatin. For lovastatin, sodium starch glycolate used as superdisintegrant in the immediate release layer and hydroxypropyl methylcellulose (HPMC) K4M and Xanthan gum used for diltiazem HCl in the controlled release layer. Sodium bicarbonate and Dicalcium phosphate was used as the gas generating agent and channeling agent respectively. Formulations have good matrix integrity and  lovastatin released within 30 min. The concentration of polymer controle the diffusion of diltiazem HCl. HPMC and Xanthan gum decrease the release of diltiazem HCl for 12 h. The release of one drug remained unaffected in presence of the other drug.25


Meka et al developed a multiple-unit minitablets based on Effervesent technique for furosemide. The system consists of core units (solid dispersion of furosemide:povidone and other excipients), and coated with an effervescent (sodium bicarbonate) layer and other one an outer polymeric layer of polymethacrylates. With the Eutragit RL30D system was floated immediately on gastric contents and was released linear on controlled manner.26


Rahman et al developed a bilayer tablet of captopril using HPMC, K-grade and mixture of citric acid and sodium bicarbonate as effervescent compound which formed the floating layer. In release layer captopril and various polymers such as HPMC-K15M, PVP-K30 and Carbopol 934p, in combination with the drug. The floating behavior the system was studies in vitro dissolution in gastric fluid having 1.2 pH. Approximately 95% drug was released in vitro, and have  floating lag time 10 min.27


Jang et al developed a GRDDS of DA-6034 (synthetic flavonoid derivative), for the treatment of gastritis by using effervescent floating matrix system (EFMS) because  its low solubility in acidic medium, which was float in gastric contents and continuously release the drug. By this system the release of DA-6034 from tablets increased in acidic media.28


Jaimini et al prepared a effervescent floating tablet of famotidine by using  two different grades of methocel (K100 and K15M) which is responcible for gel forming properties. Sodium bicarbonate as a gas-generating agent was essential to found  in vitro buoyancy. The drug release from the tablets was sufficiently sustained and non-Fickian transport of the drug from tablets was confirmed.29


(B) Non-Effervescent:

Non-effervescent floating dosage forms based on the mechanism of swelling   of exipients or bio-adhesion to GIT mucosa. Gel forming or swellable  cellulose type of hydrocolloids, polysaccharides, and matrix-forming polymers like polycarbonate, polyacrylate, polymethacrylate, and polystyrene are used as non-effervescent polymers. After swallowing this dosage form swells in contact with gastric fluids. The air entrapped within the swollen matrix imparts buoyancy to the dosage form. The so formed swollen gel-like structure acts as a reservoir and allows sustained release of drug through the gelatinous mass.30


Garse et al, prepared a non-effervescent floating tablets of labetalol hydrochloride has been developed using various grades of HPMC and Poloxamer M127 as wetting agent. The tablets formulated with HPMC K4M CR and HPMC K15M CR along with Poloxamer showed negligible floating lag time with a total floating time over 12 hrs with complete release. The formulation have good floating and swelling behaviour and drug release in a controlled manner.31


Abdelbary et al, developed Trimetazidine extended-release floating tablets by using polymers including HPMC 4000 cps, carbopol 971P, polycarbophil, and guar gum. The tablets were fabricated by dry coating technique. Stability study of the dosages form was carried out for 3 months at three different temperatures. All tablet formulas achieved <0.5 min of floating lag time, more than 12 h of floating duration, and extended t (1/2). The drug release followed zero-order kinetics.32


Elmowafy et al, developed single-unit floating matrix tablets of famotidine by the use of the low density polypropylene foam powder. The matrix integrity of prepared floating tablets is good. The differential scanning calorimetry and Fourier transform infrared spectroscopy studies revealed that changing the polymer matrix system by formulation of polymers blends resulted in formation of molecular interactions which may have implications on drug release characteristics. This was obvious from the retardation in drug release and change in its mechanistic.33


Hu et al  was developed rosiglitazone maleate floating microspheres by an emulsion-solvent diffusion method with ethyl cellulose and octadecyl alcohol as the carrier materials,  After 12 h microspheres floating was (91.45 +/- 1.62)%, and the dose loading were (9.31 +/- 0.31)% . The AUC of plasma concentration-time of the floating microspheres was equivalent to that of reference tablets. Therefore floating microspheres are a feasible approach for the sustained-release preparation of drugs which have limited absorption sites in the upper small intestine    (figure-4) .34


Figure 4. Formulation of floating hollow microsphere


Streubel et al, developed floating microparticles composed of polypropylene foam, Eudragit S, ethyl cellulose (EC), and polymethylmethaacrylate (PMMA) and were prepared by solvent evaporation technique. High encapsulation efficiencies were observed and were independent of the theoretical drug loading. Good floating behavior was observed as more than 83% of microparticles were floating for at least 8 hours. The in vitro drug release was dependent upon the type of polymer used. At similar drug loading the release rates increased in the following order PMMA < EC < Eudragit S. This could be attributed to the different permeabilities of the drug in these polymers and the drug distribution within the system.35


Regmi et al, developed  hydrodynamic balance system of ethmozine (E-HBS). In vitro release of E-HBS were shown the first order of kinetics. The gamma-scintiphotographic study showed that E-HBS remained in the human stomach for more than 6h after ingestion, much longer than the conventional tablet (1-1.5 h). The plasma concentration-time curve of E-HBS exhibited typical sustained-release characteristics. The percentage of drug released in linear (figure-5).36


Prajapati et al, developed floating matrix tablets of domperidone for increasing drug bioavailability. Hydroxypropylmethylcellulose K4M, carbopol 934P, and sodium alginate used in the tablet. Tablets were evaluated for in vitro release for 24h according to linear regression analysis. Tablets exhibited desired floating and prolonged drug release time. Carbopol decreased floating properties of tablet but were helpful to control the release rate of drug.37



The gastric retention time(GRT) of oral dosages form is affected by the several factors which is depend on the efficiency of the GR  system:38

1.      Age – Age of the people also affects the gastric empting time. Especially elderly people those over 70, have a significantly longer GRT.


2.      Gender – Mean ambulatory gastric retention time in males (3.4±0.6 hours) is less compared with their age and race matched female counterparts (4.6±1.2 hours), regardless of the weight, height and body surface.


3.      Size of dosages form - 7.5mm diameter of dosages form having better gastric residence time compare to the  9.5mm.


4.      Shape of dosages form -   Shape of the dosage form also affected the gastric emptying . Tetrahedron and ring shaped devices with a flexural modulus of 48 and 22.5 kilo pounds per square inch are reported to have better gastric retention time 90 to 100 per cent at 24 h compared with other shape.


5.      Density – Gastric retention time also dependent on the density of the dosage form. A buoyant dosage form having lower density than gastric fluids and therefore remain floating in the stomach for a long period of time.


6.      Nature of meal – Fatty acid, monoglycerides, diglycerides or indigestible polymers can change the motility pattern of the stomach to a fed state, thus decreasing the gastric emptying rate and prolonging drug release.


7.      Size of meal - Large meals tend to empty more slowly in first few hour and then more quickly compared to a small meal.



In FDDS inert fatty materials having a specific gravity of less than one can be used to decrease the hydrophilic property of formulation and hence increase buoyancy. Eg. Beeswax, fatty acids, long chain fatty alcohols. Hydrocolloids such as Acacia, pectin, Chitosan,agar, casein, bentonite, veegum, HPMC(K4M, K100M and K15M),Gellan gum(Gelrite®), Sodium CMC, MC, HPC. 20%-75% are used in formulation. Effervescent agents Sodium bicarbonate, citric acid, tartaric acid, Di-SGC (Di-Sodium Glycine Carbonate, CG (Citroglycine). 5%-60% lactose, mannitol are use as release rate accelerants. Upto 80% ethyl cellulose used as buoyancy increasing agents and Low density material such as Polypropylene foam powder (Accurel MP 1000®). Many other polymers also use in FDDS that are given as following :39


Hydroxypropyl methylcellulose (HPMC) :

Rajab et al developed a metformin HCl effervescent tablet. In this formulation HPMC was used as the hydrophilic polymer, other ingredients also incorporated such as sodium bicarbonate and stearic acid.40


Jagdale et al developed the propranolol HCl floating tablet for achieving good drug bioavailability. All floating  tablets were formulated with  HPMC K4 and hydroxypropyl cellulose. Xanthan gum also use it show  good retaining ability.41

Bomma et al, developed norfloxacin floating matrix tablet by using HPMC and xanthan gum. All formulation have non fickian diffusion release characteristics  (In vitro). Tablets retained in stomach approximately  three hours.42

Patel et al formulated floating tablet of verapamill HCl for controlled drug delivery in the Stomach. Formulation was formulated with  hydroxypropyl methylcellulose (HPMC), carbopol ,xanthan gum and effervescent agent such as citric acid and sodium bicarbonate for achieving buoyancy. Drug released form formulation in zero order kinetic and non fickian diffusion.43


Arza et al  develope swellable, floating and sustained release tablets with the combination of HPMC as hydrophilic polymer , crospovidone, sodium bicarbonate. All formulation show good swelling , drug release, floating characters  than CIFRAN OD (marketed product) when comprises with it.44


Garg  et al used hydroxypropyl methylcellulose K4M  K15M for preparation of Acyclovir floating effervescent  tablet to prolong the gastric retention time.45


Microcrystalline cellulose :

Sawicki et al  compare the utility of microcrystalline cellulose and powdered cellulose in the floating pellet cores of verapamil HCl. In this study sawicki was found that verapmil HCl release rate from coated pellets with higher amount of powdered cellulose was considerably slower than the pellets containing higher microcrystalline cellulose.[46]

Garg et al developed a floating tablet of Acyclovir for enhancing the gastric residence time. In the formulation microcrystalline cellulose used for increasing the swelling property of the Acyclovir floating tablet and other material such as HPMC, psyllium husk, sodium bicarbonate as gas generating agent was also used.45


Hydroxyethyl cellulose :

Chen et al developed a GR drug delivery system for administration of losarton. In this system chen used hydroxyethyl cellulose (HEC), sodium corboxymethyl cellulose and sodium bicarbonate and compressed at low pressure resulting tablet float over SGF for <16h and swelling 2 cm in diameter within 3 hours. Releasing of drug from the tablet was depend upon pH.19


Eudragit :

Lingam et al used Eudragit RL30D in the formation of biphasic floating drug delivery system with multiple unit mini tablet. This system based on gas formation technique to maintain the drug concentration in the plasma.24


Goole et al developed a new coated multiple unit sustained release floating system for Levodopa which is based on gas formation method. Eudragit RL30D used as film former and coating level fixed at 20% w/w.47



S. no.

Brand name

Delivery system

Drug and Dose

Company name


Madopar® HBS

(Prolopa® HBS)


CR capsule


And L-Dopa (100mg)

Roche Products, USA


Cifran OD®

Gas-generating floating form

Ciprofloxacin (1gm)

Ranbaxy, India


Liquid Gaviscon®

Effervescent Floating liquid

alginate preparations

Al hydroxide (95 mg),

Mg Carbonate (358 mg)

GlaxoSmithkline, India




gel forming FDDS

Ferrous sulphate

Ranbaxy, India



Floating liquid

alginate preparation

Al – Mg  antacid

Pierre Fabre Drug, France




floating capsule

Misoprostol (100µg/200µg)

Pharmacia, USA



Floating capsule

Diazepam (15mg)

Hoffmann-LaRoche, USA



Meka et al developed FDDS with multiple unit mini tablet. System consist of three successive. Eudragit RL30D was used in this system as outer gas entrapped polymeric membrane layer.48


Zhai et al prepared a phenols gastric tablet by using Eudragit IV, HPMC and octadecanol.49



Some of the marketed floating drug delivery system based formulations are listed in above table:50,51


Figure 5.  Working principle of hydrodynamically balanced system.



1.      Improved the absorption of drug because FDDS increased the gastric retention time and dosage form spend long time in the stomach.


2.      It is important for drug which is absorbed through the stomach.


3.      Minimizing the mucosal irritation due to acidic drug. For these type of drug formulated by Hydrodynamically Balanced System which release the drug at controlled rate.


4.      When there is vigorous intestinal movement and a short transit time as might occur in certain type of diarrhoea, poor absorption is expected under such circumstances it may be advantageous to keep the drug in floating condition in stomach to get a relatively better response.




1.      Drug which have solubility or stability problem in GIT are not suitable for this system.

2.      In gastric emptying time high variability occur due to its all or non emptying process.

3.      It is require high level of fluid in the stomach.

4.      Drug that causes irritation to the gastric mucosa are also not suitable for FDDS.



GRDDS offers various potential advantages for drug with poor bioavailability due their absorption is restricted to the upper GIT and they can be delivered efficiently thereby maximizing their absorption and enhancing bioavailability. Several approaches are currently used to prolong gastric retention time. These include floating drug delivery systems, swelling and expanding systems, bioadhesive systems, ion exchange systems, high density systems and other delayed gastric emptying excipient. Floating tablets provide a dosage form which is stable and provides a sustained release drug delivery. Now –a-days lot of work is running to develop different types of gastroretentive delivery systems of various drugs. Day by day the FDDS shows more promise for a bright future.



1.       Streubel A, Siepmann J, Bodmeier R. Gastroretentive drug delivery system. Expert Opin Drug Deliv 2006; 3(2): 217-33.

2.       Garg R, Gupta GD. Progress in controlled gastroretentive delivery systems. Trop. J Pharm Res 2008; 7(3): 1055-66

3.       Dr  Jose Gutierrez - Rocca , Hossein Omid ian and Khalid Shah. Progresses in gastroretentive drug delivery system. Nova Southeastern University, 2003, 152.

4.       Tortora GJ and Grabowski SR: Principles of Anatomy and Physiology. John Willey and Sons, Tenth Edition 2002.

5.       Nur AO and Zhang JS: Captropril floating and bioadhesive tablets: design and release kinetics. Drug Dev Ind Pharm 2000; 26(9): 965-969.

6.       Huang Y, Leobandung W, Foss A, Peppas NA. Molecular aspects of muco- and bioadhesion: tethered structures an site-specific surfaces. J Control Release 2000; 65(1-2): 63-71.

7.       Garg Sanjay; Sharma Shringi. Business Briefing Pharmtech, 2003, 160-166.

8.       Sangekar S. International Journal of Pharmaceutics, 1987, 35(3), 34-53.

9.       Neena Washington, Clive Washington and Clive G.Wilson , Physiological Pharmaceutics Barriers to drug absorption, Second Edition, 2001, 81-90.

10.     Singh BN and Kim HK: Floating drug delivery systems: An approach to oral controlled drug delivery via gastric retention. J Control Rel 2000; 63: 235-259.

11.     Atyabi F, Sharma HL, Mohammad HAH and Fell JT: In vivo evaluation of a novel gastroretentive formulation based on ion exchange resins. J Control Release 1996; 58: 105-113.

12.     Xu, W. L, Tu, X. D. and Lu, Z. D. :Development of gentamicin sulphate sustained release tablet remaining floating in stomach, Yao Xue Xue Bao, 1991, 26, 541-545.

13.     Huang Y, Leobandung W, Foss A, Peppas NA. Molecular aspects of muco- and bioadhesion: tethered structures and site-specific surfaces. J Control Release 2000; 65(1-2): 63-71.

14.     Hwang SJ, Park H and Park K: Gastric retentive drug-delivery systems. Crit Rev Ther Drug Carrier Syst 1998; 15(3): 234-284.

15.     Praveen Nasa: Floating system: a novel approaches toward GRDDS,IJPPS; 2010; 2, 1-2.

16.     Samip Shah and Shridhar Pandya: floating drug delivery system; IJPSR 2010, vol. 1, 15-16.

17.     Rubinstein A, Friend DR. Specific delivery to the gastrointestinal tract, in: Domb A.J (Ed.), Polymeric SiteSpecific Pharmacotherapy, Wiley, Chichester 1994; 282283.

18.        Asnaashari, S., Khoei, N.S., Zarrintan, M.H., Adibkia, K. and Javadzadeh, Y. Prep. and evaluation of novel metronidazole sustained release and floating matrix tablets. Pharm Dev Technol, 2010

19.     Chen, R.-N., Ho, H.-O., Yu, C.-Y. and Sheu, M.-T.Development of swelling/floating gastroretentive drug delivery system based on a combination of hydroxyethyl cellulose and sodium carboxymethyl cellulose for Losartan Eur J Pharm Sci, 2010, Vol. 39(1-3), pp. 82-89

20.     Nagarwal, R.C., Ridhurkar, D.N. and Pandit, J.K. In vitro release kinetics and bioavailability of gastroretentive cinnarizine hydrochloride tablet. AAPS PharmSciTech,2010, Vol. 11(1), pp. 294-303

21.     Bomma, R., Naidu, R.A.S., Yamsani, M.R. and Veerabrahma, K. Development and evaluation of gastroretentive norfloxacin floating tablets. Acta Pharm, 2009, Vol. 59(2), pp. 211-221

22.     Ichikawa, M., Watanabe, S. and Miyake, Y. A new multiple-unit oral floating dosage system. I: Preparation and in vitro evaluation of floating and sustained-release characteristics. J Pharm Sci, 1991, Vol. 80(11), pp. 1062-1066

23.     Bandari, S., Eaga, C.M., Thadishetty, A. and Yamsani, M.R. Formulation and evaluation of multiple tablets as a biphasic gastroretentive floating drug delivery system for fenoverine. Acta Pharm,2010, Vol. 60(1), pp. 89-97

24.     Lingam, M., Ashok, T., Venkateswarlu, V. and Rao, Y.M; Design and evaluation of a novel matrix type multiple units as biphasic gastroretentive drug delivery systems. AAPS PharmSciTech, 2008, Vol. 9(4), pp. 1253-1261

25.     Kulkarni, A.S. and Bhatia, M.S. Design of floating bilayer tablets of diltiazem hydrochloride and lovastatin. PDA J Pharm Sci Technol,2008, Vol. 62(5), pp. 344-352

26.     Meka, L., Kesavan, B., Kalamata, V.N., Eaga; Design and evaluation of polymeric coated minitablets as multiple unit gastroretentive floating drug delivery systems for furosemide. J Pharm Sci, 2009, Vol. 98(6), pp. 2122-2132

27.     Rahman, Z., Ali, M. and Khar, R. Design and evaluation of bilayer floating tablets of captopril. Acta Pharm, 2006, Vol. 56(1), pp. 49-57

28.     Jang, S.W., Lee, J.W., Park, S.H., Kim, J.H., Gastroretentive drug delivery system of DA-6034, a new flavonoid derivative, for the treatment of gastritis. Int J Pharm, 2008, Vol. 356(1-2), pp. 88-94

29.     Jaimini, M., Rana, A.C. and Tanwar, Y.S. Formulation and evaluation of famotidine floating tablets. Curr Drug Deliv, 2007, Vol. 4(1), pp. 51-55

30.     Hilton AK, Deasy PB. In vitro and in vivo evaluation of an oral sustained release floating dosage form of amoxicillin trihydrate. Int J Pharm 1992; 86: 79-88

31.     Garse, H., Vij, M., Yamgar, M., Kadam, V. and Hirlekar, R. Formulation and evaluation of a gastroretentive dosage form of labetalol hydrochloride. Arch Pharm Res, 2010, Vol. 33(3), pp. 405-410

32.     Abdelbary, A., El-Gazayerly, O.N., El-Gendy, N.A. and Ali, A.A. Floating Tablet of Trimetazidine Dihydrochloride: An Approach for Extended Release with Zero-Order Kinetics.AAPS PharmSciTech,2010

33.     Elmowafy, E.M., Awad, G.A.S., Mansour, S. and El-Shamy, A.E.-H.A. Release mechanisms behind polysaccharides-based famotidine controlled release matrix tablets.AAPS PharmSciTech,2008, Vol. 9(4), pp. 1230-1239

34.     Hu, L.-D., Xing, Q.-B., Shang, C., Liu, W., Liu, C., Luo, Z.-L. and Xu, H.-X. Preparation of rosiglitazone maleate sustained-release floating microspheres for improved bioavailability. Pharmazie, 2010, Vol. 65(7), pp. 477-480

35.     Streubel, A., Siepmann, J. and Bodmeier, R. Multiple unit gastroretentive drug delivery systems: a new preparation method for low density microparticles. J Microencapsul,2003, Vol. 20(3), pp. 329-347

36.     Regmi, B.M., Liu, J.P. and Tu, X.D. Studies on ethmozine sustained-release tablet remaining-floating in stomach.Yao Xue Xue Bao, 1996, Vol. 31(1), pp. 54-58

37.     Prajapati, S.T., Patel, L.D. and Patel, D.M. Studies on formulation and in vitro evaluation of floating matrix tablets of domperidone. Indian J Pharm Sci, 2009, Vol. 71(1), pp. 19-23

38.     Bhavna V, Khopade AJ, Shelly WD and Jain NK: Targeted oral drug delivery. Indian Drugs 1996; 33: 365-373

39.     Shah S.H., Patel J.K., Patel N.V.; stomach specific floating drug delivery syatem; IJPTR;2009, pp. 629-630

40.     Rajab, M., Jouma, M., Neubert, R.H. and Dittgen, M. Optimization of a metformin effervescent floating tablet containing hydroxypropylmethylcellulose and stearic acid. Pharmazie, 2010, Vol. 65(2), pp. 97-101

41.     Jagdale, S.C., Agavekar, A.J., Pandya, S.V., Kuchekar, B.S. and Chabukswar, A.R. Formulation and evaluation of gastroretentive drug delivery system of propranolol hydrochloride. AAPS PharmSciTech, 2009, Vol. 10(3), pp. 1071-1079

42.     Bomma, R., Naidu, R.A.S., Yamsani, M.R. and Veerabrahma, K. Development and evaluation of gastroretentive norfloxacin floating tablets. Acta Pharm, 2009, Vol. 59(2), pp. 211-221

43.     Patel, A., Modasiya, M., Shah, D. and Patel, V. Development and in vivo floating behavior of verapamil HCl intragastric floating tablets. AAPS PharmSciTech, 2009, Vol. 10(1), pp. 310-315

44.     Arza, R.A.K., Gonugunta, C.S.R. and Veerareddy, P.R. Formulation and evaluation of swellable and floating gastroretentive ciprofloxacin hydrochloride tablets. AAPS PharmSciTech, 2009, Vol. 10(1), pp. 220-226

45.     Garg, R. and Gupta, G.D. Preparation and evaluation of gastroretentive floating tablets of acyclovir. Curr Drug Deliv, 2009, Vol. 6(5), pp. 437-443

46.     Sawicki, W., ?unio, R., Walentynowicz, O. and Kubasik-Juraniec, J. aInfluence of the type of cellulose on properties of multi-unit target releasing in stomach dosage form with verapamil hydrochloride. Acta Pol Pharm, 2007, Vol. 64(1), pp. 81-88

47.     Goole, J., Deleuze, P., Vanderbist, F. and Amighi, K. New levodopa sustained-release floating minitablets coated with insoluble acrylic polymer. Eur J Pharm Biopharm, 2008, Vol. 68(2), pp. 310-318

48.     Meka, L., Kesavan, B., Chinnala, K.M., Vobalaboina, V. and Yamsani, M.R. Preparation of a matrix type multiple-unit gastro retentive floating drug delivery system for captopril based on gas formation technique: in vitro evaluation. AAPS PharmSciTech, 2008, Vol. 9(2), pp. 612-619

49.     Zhai, X.-L., Ni, J. and Gu, Y.-L. Study on preparation of phenols gastric floating tablet Zhongguo Zhong Yao Za Zhi, Beijing University of Traditional Chinese Medicine, Beijing 100102, China., 2008, Vol. 33(1), pp. 31-34

50.     Vyas SP, Khar RK. Gastroretentive systems. In: Controlled drug Delivery. Vallabh Prakashan, Delhi, India. 2006. pp.197-217

51.     Chawla G, Gupta P, Bansal AK. Gastroretentive drug delivery systems. In: Jain NK. editor. Progress in controlled and novel drug delivery systems. CBS Publishers and Distributors. New Delhi. 2004. p. 76-97






Received on 25.03.2011       Modified on 03.04.2011

Accepted on 08.04.2011      © RJPT All right reserved

Research J. Pharm. and Tech. 4(7): July 2011; Page 1026-1032